180 related articles for article (PubMed ID: 9321739)
1. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
Wang D; Strandgaard S
J Hypertens; 1997 Sep; 15(9):925-33. PubMed ID: 9321739
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
Rahbari-Oskoui F; Williams O; Chapman A
Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
[TBL] [Abstract][Full Text] [Related]
3. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease.
Schrier RW
J Am Soc Nephrol; 2009 Sep; 20(9):1888-93. PubMed ID: 19696226
[TBL] [Abstract][Full Text] [Related]
4. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members.
Barrett BJ; Foley R; Morgan J; Hefferton D; Parfrey P
Kidney Int; 1994 Oct; 46(4):1118-23. PubMed ID: 7861706
[TBL] [Abstract][Full Text] [Related]
5. Hypertension in autosomal dominant polycystic kidney disease.
Chapman AB; Stepniakowski K; Rahbari-Oskoui F
Adv Chronic Kidney Dis; 2010 Mar; 17(2):153-63. PubMed ID: 20219618
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk in polycystic kidney disease].
Di Lorenzo A; Stallone G; Infante B; Grandaliano G; Schena FP
G Ital Cardiol (Rome); 2015 Sep; 16(9):479-84. PubMed ID: 26418387
[TBL] [Abstract][Full Text] [Related]
7. Borderline hypertensive autosomal dominant polycystic kidney disease patients have enhanced production of renal dopamine. Normalization of renal haemodynamics by DOPA infusion.
Barendregt JN; Florijn KW; Muizert Y; Chang PC
Nephrol Dial Transplant; 1995; 10(8):1332-41. PubMed ID: 8538923
[TBL] [Abstract][Full Text] [Related]
8. Autosomal-dominant polycystic kidney disease and hypertension: a review.
Florijn KW; van Saase JL; Breuning MH; Chang PC
Contrib Nephrol; 1992; 97():71-92. PubMed ID: 1386018
[No Abstract] [Full Text] [Related]
9. Screening of QTc interval and global autonomic activity in autosomal dominant polycystic kidney disease and atherosclerotic renal artery stenosis hypertensive patients.
Lai S; Perrotta AM; Bagordo D; Mazzaferro S; Menè P; Gigante A; Tinti F; Galani A; Cianci R
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6333-6338. PubMed ID: 34730214
[TBL] [Abstract][Full Text] [Related]
10. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease.
Torres VE; Wilson DM; Burnett JC; Johnson CM; Offord KP
Mayo Clin Proc; 1991 Oct; 66(10):1010-7. PubMed ID: 1921483
[TBL] [Abstract][Full Text] [Related]
11. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
[TBL] [Abstract][Full Text] [Related]
12. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
Chapman AB; Johnson A; Gabow PA; Schrier RW
N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
[TBL] [Abstract][Full Text] [Related]
13. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease.
Tkachenko O; Helal I; Shchekochikhin D; Schrier RW
Curr Hypertens Rev; 2013 Feb; 9(1):12-20. PubMed ID: 23971639
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease.
Chapman AB; Schrier RW
Semin Nephrol; 1991 Nov; 11(6):653-60. PubMed ID: 1767138
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.
Schrier RW
Pharmacol Res; 2016 Dec; 114():166-168. PubMed ID: 27794499
[TBL] [Abstract][Full Text] [Related]
16. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
Lawson CR; Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
[TBL] [Abstract][Full Text] [Related]
17. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease.
Loghman-Adham M; Soto CE; Inagami T; Cassis L
Am J Physiol Renal Physiol; 2004 Oct; 287(4):F775-88. PubMed ID: 15187005
[TBL] [Abstract][Full Text] [Related]
18. A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease.
Kocyigit I; Yilmaz MI; Unal A; Ozturk F; Eroglu E; Yazici C; Orscelik O; Sipahioglu MH; Tokgoz B; Oymak O
Am J Nephrol; 2013; 38(3):218-25. PubMed ID: 23988725
[TBL] [Abstract][Full Text] [Related]
19. Role of renin-angiotensin-aldosterone system gene polymorphisms and hypertension-induced end-stage renal disease in autosomal dominant polycystic kidney disease.
Ramanathan G; Elumalai R; Periyasamy S; Lakkakula B
Iran J Kidney Dis; 2014 Jul; 8(4):265-77. PubMed ID: 25001132
[TBL] [Abstract][Full Text] [Related]
20. Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression.
Hian CK; Lee CL; Thomas W
Nephron; 2016; 134(2):59-63. PubMed ID: 27476173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
